leisure time -WSS

leisure time

author：hotspot 2025-09-30 17:45:09 - browse：17

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Christmas in the PICU brings some surprising joy

WSS

Readout Newsletter: XBI biotech index, Akero Therapeutics

Why Sanofi got shellacked over its spinoff

Meta's Zuckerberg and Chan on track to put $50 billion into science

Maker of FluMist seeks to allow at

Violet CEO on training clinicians to promote more inclusive care

Medicare Advantage beneficiaries sue Humana over algorithm use

hotspot

leisure time

entertainment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Christmas in the PICU brings some surprising joy

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: New research from Sanofi, Regeneron, etc.

23andMe had bad news about my health. I wish a person had delivered it

Physician subsidies by hospitals soar in wake of No Surprises Act

Trump demands the U.S. pay no more for drugs than other countries … again

In Spain, a hospital brews its own CAR

Medicare details structure of new drug price negotiation program

Traditional Chinese medicine benefits explored in new JAMA study

Wikipedia

Prime Medicine, Myeloid Therapeutics clash over genome

Christmas in the PICU brings some surprising joy

Medicare drug price negotiation hasn't dried up venture capital

Medtronic CEO on promising devices for diabetes, hypertension

Violet CEO on training clinicians to promote more inclusive care

Senate panel to vote on hospitals, PBMs, prisoner care

Wikipedia

focus

focus

hotspot